Haleon (NYSE:HLN) PT Raised to $10.95 at Morgan Stanley

Haleon (NYSE:HLN) had its target price upped by Morgan Stanley from $9.90 to $10.95 in a report released on Friday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on the company. The Goldman Sachs Group cut Haleon from a buy rating to a neutral rating in a report on Tuesday, August 6th. Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They set a buy rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Haleon presently has a consensus rating of Moderate Buy and an average target price of $10.95.

Haleon Stock Performance

Shares of NYSE:HLN opened at $10.64 on Friday. Haleon has a twelve month low of $7.70 and a twelve month high of $10.76. The firm has a market cap of $48.56 billion, a PE ratio of 35.45, a price-to-earnings-growth ratio of 3.10 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The business has a fifty day moving average of $9.80 and a 200-day moving average of $8.89.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter in the previous year, the business earned $0.08 earnings per share. On average, equities research analysts predict that Haleon will post 0.46 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s payout ratio is 33.33%.

Institutional Investors Weigh In On Haleon

Several institutional investors have recently bought and sold shares of HLN. Clearbridge Investments LLC lifted its stake in Haleon by 44.6% in the 1st quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock valued at $326,415,000 after acquiring an additional 11,865,076 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after acquiring an additional 8,423,475 shares during the last quarter. Martin Investment Management LLC increased its holdings in shares of Haleon by 12,018.4% during the 1st quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after acquiring an additional 4,426,375 shares during the last quarter. Sculptor Capital LP increased its holdings in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Haleon by 95.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock worth $16,143,000 after acquiring an additional 954,622 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.